Compound comparison · Research use only

Tesamorelin vs CJC-1295

Tesamorelin is a synthetic GHRH(1-44) analog (trans-3-hexenoic acid-modified). CJC-1295 is a modified GRF(1-29), protease-resistant synthetic GHRH(1-29) analog (no albumin-binding DAC). They are different materials with different identities and different research literatures; the table below sets the two identities side by side, the sections after it summarise what each is studied for, and the certificate rows show how each has tested.

Identity

Tesamorelin and CJC-1295 side by side

FieldTesamorelinCJC-1295
Catalogue nameTesamorelinCJC-1295
TypeSingle peptideSingle peptide
ClassSynthetic GHRH(1-44) analog (trans-3-hexenoic acid-modified)Modified GRF(1-29), protease-resistant synthetic GHRH(1-29) analog (no albumin-binding DAC)
ComponentsSingle compoundSingle compound
Molecular formulaC221H366N72O67SC152H252N44O42
Molecular weight5135.89 Da3367.97 Da
Sequence length44 residues29 residues
CAS or identifier218949-48-5863288-34-0
Form suppliedLyophilized powderLyophilized powder
Sizes10mg5mg
Price from$90$45
Documented HPLC results10 (99.12 to 99.93%)4 (99.18 to 99.92%)
Testing laboratoriesAccurate Test Labs, Freedom DiagnosticsAccurate Test Labs, Freedom Diagnostics

Identity fields come from the catalogue entry for each compound. Certificate counts are documented third-party HPLC results with a published certificate; image-only documents are excluded from the counts.

Mechanisms

What the research literature describes

Tesamorelin

  • Growth Hormone Secretagogue GHRH-R Agonism
  • Visceral Adipose Signalling Lipolysis
  • Cognitive & Brain Research Neuroprotection

CJC-1295

  • GHRH Receptor Activation GHRH-R Agonist
  • Pulsatile GH Secretion Pulsatile GH
  • GH/IGF-1 Axis Response IGF-1 Axis
Research focus

What each is studied for

Tesamorelin

  • Visceral Fat & Body Composition Metabolic
  • Brain Structure & Function Cognitive Research
  • GH/IGF-1 Axis Endocrinology
  • Lipid & Cardiovascular Markers Cardiometabolic

CJC-1295

  • Pulsatile GH Research Endocrinology
  • GHRH Analog Comparison Pharmacology
  • CJC / Ipamorelin Synergy Combination Research
  • GHRH Axis Models Animal Models

Headings name the mechanisms and research applications described for each compound; the full text of each sits on the compound monograph linked below. They summarise findings reported in preclinical models. They describe what has been studied, not outcomes in people or animals outside the laboratory.

Go deeper

Catalogue, monographs and certificates

What is the difference between Tesamorelin and CJC-1295?

Tesamorelin is a synthetic GHRH(1-44) analog (trans-3-hexenoic acid-modified); CJC-1295 is a modified GRF(1-29), protease-resistant synthetic GHRH(1-29) analog (no albumin-binding DAC). Tesamorelin has 44 residues and CJC-1295 has 29. Their molecular identities, the models they have been studied in and their certificate records are all listed on this page.

Are Tesamorelin and CJC-1295 sold together?

No. Eon Peptides lists them as separate catalogue items, each with its own sizes and its own certificates.

How has each tested?

Tesamorelin: 10 documented third-party HPLC results from 99.12% to 99.93%. CJC-1295: 4 documented results from 99.18% to 99.92%. Every certificate is published and linked from each compound's lab results page.

Which one should a research project use?

That depends on the pathway and model under study, which is a scientific question this page does not answer. What it does is put the identities, the described mechanisms and the analytical records side by side so the choice can be made on documented facts. Both materials are for laboratory research use only.

For research use only. Not for human or veterinary use. Nothing on this page describes or recommends use in people or animals.